{"id":12109,"date":"2018-11-30T09:49:20","date_gmt":"2018-11-30T14:49:20","guid":{"rendered":"https:\/\/medicarereport.org\/?p=12109"},"modified":"2018-11-30T09:49:20","modified_gmt":"2018-11-30T14:49:20","slug":"a-loss-for-the-rest-of-us-an-fda-approval-is-a-boon-for-a-drug-maker-but-could-come-at-a-major-cost-for-patients","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=12109","title":{"rendered":"\u2018A loss for the rest of us\u2019: An FDA approval is a boon for a drug maker, but could come at a major cost for patients"},"content":{"rendered":"<p>(By Meghana Keshavan for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap-wrap\"><span class=\"big-cap\">V<\/span><\/span>ickie Moored can walk again. Her words don\u2019t slur, her vision isn\u2019t blurred, and she no longer collapses every day. <a href=\"https:\/\/www.statnews.com\/2018\/11\/30\/fda-approval-lems-drug-costs\/?utm_campaign=KHN%3A%20Daily%20Health%20Policy%20Report&amp;utm_source=hs_email&amp;utm_medium=email&amp;utm_content=67947654&amp;_hsenc=p2ANqtz-8TcQTX9nGCf1C-x30g9leI0zSmuf4rKc1tFgro7ScqwmSl17VgO4ANSAYQmGp0m879rBrQPrv84F8WadZnYvM-EqnnmA&amp;_hsmi=67947654\">Continue reading article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Meghana Keshavan for STAT) Vickie Moored can walk again. Her words don\u2019t slur, her vision isn\u2019t blurred, and she<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31,15],"tags":[],"class_list":["post-12109","post","type-post","status-publish","format-standard","hentry","category-fda","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12109"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12109\/revisions"}],"predecessor-version":[{"id":12110,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12109\/revisions\/12110"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}